Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00420927

Public ClinicalTrials.gov record NCT00420927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)

Study identification

NCT ID
NCT00420927
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Abbott
Industry
Enrollment
1,032 participants

Conditions and interventions

Interventions

  • adalimumab Biological
  • methotrexate Drug
  • placebo Biological

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Last update posted
Apr 17, 2012

2006 – 2010

United States locations

U.S. sites
49
U.S. states
21
U.S. cities
48
Facility City State ZIP Site status
Site Reference ID/Investigator# 4560 Birmingham Alabama 35205
Site Reference ID/Investigator# 4547 Birmingham Alabama 35294-7201
Site Reference ID/Investigator# 6222 Huntsville Alabama 35801
Site Reference ID/Investigator# 4537 Mobile Alabama 36608
Site Reference ID/Investigator# 6758 Tuscaloosa Alabama 35406
Site Reference ID/Investigator# 9323 Hemet California 92543
Site Reference ID/Investigator# 4568 La Jolla California 92037-0943
Site Reference ID/Investigator# 4535 Palm Desert California 92260
Site Reference ID/Investigator# 4571 Santa Monica California 90404
Site Reference ID/Investigator# 9271 Torrance California 90505
Site Reference ID/Investigator# 10746 Victorville California 92395
Site Reference ID/Investigator# 4559 Denver Colorado 80230
Site Reference ID/Investigator# 6229 Aventura Florida 33180
Site Reference ID/Investigator# 10603 Lake Mary Florida 32746
Site Reference ID/Investigator# 9325 Orange Park Florida 32073
Site Reference ID/Investigator# 4550 Palm Harbor Florida 34684
Site Reference ID/Investigator# 4570 Sarasota Florida 34239
Site Reference ID/Investigator# 4601 Tampa Florida 33614
Site Reference ID/Investigator# 4552 Vero Beach Florida 32960
Site Reference ID/Investigator# 10745 Meridian Idaho 83642
Site Reference ID/Investigator# 4548 Chicago Illinois 60612
Site Reference ID/Investigator# 4557 Springfield Illinois 62704
Site Reference ID/Investigator# 4605 Wichita Kansas 67203
Site Reference ID/Investigator# 10741 Wheaton Maryland 20902
Site Reference ID/Investigator# 6417 Fall River Massachusetts 02720
Site Reference ID/Investigator# 4561 Dover New Hampshire 03820
Site Reference ID/Investigator# 11222 Freehold New Jersey 07728
Site Reference ID/Investigator# 6228 Passaic New Jersey 07055
Site Reference ID/Investigator# 4544 Albuquerque New Mexico 87102
Site Reference ID/Investigator# 4534 Orchard Park New York 14127
Site Reference ID/Investigator# 9324 Plainview New York 11803
Site Reference ID/Investigator# 4600 Smithtown New York 11787
Site Reference ID/Investigator# 12821 The Bronx New York 10461
Site Reference ID/Investigator# 4549 Mayfield Village Ohio 44143
Site Reference ID/Investigator# 6227 Bend Oregon 97701
Site Reference ID/Investigator# 4546 Duncansville Pennsylvania 16635
Site Reference ID/Investigator# 4564 West Reading Pennsylvania 19611-1124
Site Reference ID/Investigator# 4558 Wexford Pennsylvania 15090
Site Reference ID/Investigator# 4533 Charleston South Carolina 29406
Site Reference ID/Investigator# 7482 Greenville South Carolina 29601
Site Reference ID/Investigator# 10743 Jackson Tennessee 38305
Site Reference ID/Investigator# 4562 Nashville Tennessee 37205
Site Reference ID/Investigator# 4536 Dallas Texas 75231
Site Reference ID/Investigator# 4538 Houston Texas 77074
Site Reference ID/Investigator# 6899 San Antonio Texas 78217
Site Reference ID/Investigator# 6381 Tyler Texas 75701
Site Reference ID/Investigator# 10744 Seattle Washington 98133
Site Reference ID/Investigator# 4545 Glendale Wisconsin 53217
Site Reference ID/Investigator# 4572 Oak Creek Wisconsin 53154

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00420927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 17, 2012 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00420927 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →